human
respiratori
syncyti
viru
hrsv
lead
caus
acut
respiratori
ill
young
children
worldwid
reliabl
detect
identif
hrsv
subgroup
b
infect
essenti
accur
diseas
burden
estim
anticip
licensur
novel
hrsv
vaccin
immunotherapi
ensur
continu
reliabl
molecular
assay
must
remain
current
evolv
viru
strain
develop
hrsv
subgroupspecif
realtim
rtpcr
rrtpcr
assay
detect
subgroup
identif
use
primer
subgroupspecif
probe
target
conserv
region
nucleoprotein
gene
combin
singl
duplex
reaction
use
genom
sequenc
data
current
avail
genbank
assay
valid
analyt
sensit
specif
reproduc
clinic
perform
geograph
divers
collect
viral
isol
respiratori
specimen
direct
comparison
establish
panhrsv
rrtpcr
refer
test
assay
sensit
reproduc
detect
copiesreact
target
rna
assay
specif
show
amplif
panel
common
respiratori
pathogen
predict
silico
primerprob
analysi
duplex
rrtpcr
assay
base
current
avail
genom
sequenc
data
permit
rapid
sensit
specif
detect
subgroup
identif
hrsv
hrsv
major
caus
sever
acut
respiratori
ill
infant
young
children
worldwid
nair
et
al
two
hrsv
subgroup
b
multipl
genotyp
within
subgroup
describ
mufson
et
al
peret
et
al
natur
human
infect
protect
homolog
subgroup
virus
pronounc
heterolog
subgroup
mufson
et
al
find
confirm
anim
challeng
studi
johnson
et
al
studi
suggest
infect
hrsv
subgroup
virus
yield
sever
infect
subgroup
b
hall
et
al
laham
et
al
walsh
et
al
although
studi
report
signific
differ
devincenzo
fodha
et
al
molecular
assay
discrimin
hrsv
subgroup
would
facilit
studi
preval
subgroup
potenti
differ
clinic
present
immun
respons
subgroup
may
eventu
help
better
inform
develop
hrsv
vaccin
immunotherapi
vandini
et
al
reliabl
method
detect
hrsv
may
use
clinic
manag
accur
diseas
burden
estim
wherea
antigenbas
hrsv
assay
proven
use
clinic
set
test
infant
young
children
molecular
diagnost
method
sensit
gener
particularli
older
children
adult
often
present
low
viral
load
later
ill
mahoni
given
inher
design
advantag
wide
gener
use
realtim
rtpcr
rrtpcr
assay
hrsv
detect
discrimin
two
hrsv
subgroup
avail
kuyper
et
al
liu
et
al
perkin
et
al
van
elden
et
al
howev
weak
inher
molecular
assay
suscept
pathogen
strain
variat
evolv
overtim
lead
primerprob
mismatch
potenti
fals
neg
result
suss
et
al
sloot
remain
viabl
molecular
assay
must
evolv
pathogen
instruct
kamau
et
al
recent
describ
failur
detect
hrsv
among
immunofluoresc
assay
ifa
posit
specimen
use
wide
use
multiplex
respiratori
pathogen
rrtpcr
assay
gunson
et
al
acquir
hrsv
primerprob
sequenc
assay
report
van
elden
et
al
investig
reveal
ifapositiverrtpcrneg
sampl
collect
hrsv
epidem
season
kilifi
kenya
contain
new
hrsv
b
strain
polymorph
rrtpcr
probe
region
hinder
anneal
author
note
failur
detect
strain
could
advers
affect
studi
use
assay
anderson
et
al
choudhari
et
al
gimferr
et
al
address
develop
valid
novel
duplex
rrtpcr
assay
use
current
hrsv
genom
sequenc
data
avail
genbank
assay
allow
sensit
specif
detect
subgroup
identif
hrsv
includ
possibl
dual
infect
threehundr
thirtyfour
hrsv
posit
respiratori
sampl
avail
assay
develop
specimen
origin
submit
cdc
support
public
health
surveil
outbreak
respons
previous
test
multipl
respiratori
pathogen
specimen
continu
store
includ
mix
respiratori
specimen
children
adult
acut
respiratori
infect
us
ii
nasopharing
aspir
young
children
month
hospit
sever
acut
respiratori
infect
brazil
iii
combin
nasopharyng
oropharyng
swab
specimen
viral
transport
media
obtain
mostli
children
present
health
clinic
acut
respiratori
ill
kenya
kenya
kim
et
al
iv
respiratori
swab
specimen
collect
guatemala
guatemala
tiblisi
georgia
respect
specimen
previous
test
human
rnase
p
monitor
extract
integr
absenc
rrtpcr
inhibitor
nineteen
genet
divers
hrsv
isol
also
avail
test
total
hrsv
whole
genom
sequenc
avail
genbank
februari
hrsv
hrsv
b
download
align
use
mafft
implement
geneiou
http
wwwgeneiouscom
primersprob
set
select
use
primer
express
softwar
thermo
fisher
scientif
waltham
usa
visual
inspect
follow
realtim
hydrolysi
probe
assay
design
guidelin
rodriguez
et
al
potenti
interfer
sequenc
secondari
structur
assess
target
region
use
mfold
web
server
zuker
primerprob
target
conserv
region
hrsv
nucleoprotein
n
gene
design
discrimin
hrsv
subgroup
b
compat
duplex
reaction
primerprob
synthes
cdc
biotechnolog
core
facil
probe
hplcpurifi
minim
overlap
dye
emiss
spectra
hrsv
probe
label
fam
hrsv
b
probe
label
cal
fluor
red
probe
intern
quench
black
hole
quencher
endlabel
prevent
probe
extens
taq
polymeras
primer
probe
sequenc
list
tabl
total
nucleic
acid
extract
clinic
specimen
use
viru
isol
use
extract
system
follow
manufactur
instruct
biomerieux
inc
durham
nc
extract
store
use
duplex
rrtpcr
assay
subgroup
hrsv
develop
follow
amplif
condit
previous
describ
cdc
refer
rrtpcr
panhrsv
assay
distinguish
hrsv
subgroup
fri
et
al
briefli
assay
perform
reaction
contain
forward
revers
primer
hrsv
probe
hrsv
b
probe
extract
rna
appli
biosystem
fast
dx
realtim
pcr
instrument
thermo
fisher
scientif
use
agpathid
onestep
rtpcr
kit
appli
biosystemslif
technolog
thermocycl
condit
consist
min
revers
transcript
min
activ
taq
polymeras
cycl
min
run
includ
one
viral
templat
control
see
one
nontempl
control
specimen
consid
posit
hrsv
b
welldefin
fluoresc
curv
cross
auto
threshold
set
within
cycl
specif
duplex
hrsv
rrtpcr
evalu
test
respiratori
pathogen
rna
dna
genom
also
use
agpathid
onestep
rtpcr
kit
valid
simultan
test
rna
dna
pathogen
weinberg
et
al
hrsv
posit
rna
control
templat
synthes
clone
usa
inc
http
wwwgenscriptcom
control
templat
contain
primerprob
sequenc
duplex
hrsv
b
panhrsv
rnp
rrtpcr
assay
arrang
one
continu
sequenc
cap
promot
sequenc
insert
sequenc
confirm
runoff
rna
transcript
prepar
use
megascript
kit
purifi
use
megaclear
kit
thermo
fisher
scientif
transcript
quantit
perform
qubit
fluoromet
thermo
fisher
scientif
sequenc
select
oligonucleotid
synthesi
multipl
primerprob
set
compar
optim
perform
four
repres
hrsv
b
isol
primerprob
concentr
determin
crosstitr
adjust
achiev
compar
ct
valu
refer
panhrsv
assay
singl
primer
pair
target
nucleoprotein
gene
two
subgroup
discrimin
probe
perform
singl
duplex
reaction
select
studi
duplex
assay
evalu
divers
hrsv
isol
staff
blind
subgroup
isol
correctli
identifi
duplex
assay
well
detect
hrsv
b
mix
reaction
supplementari
tabl
estim
analyt
sensit
rrtpcr
assay
serial
dilut
rna
transcript
prepar
mm
trisedta
buffer
contain
yeast
trna
test
replic
limit
detect
hrsv
b
yield
replic
posit
rang
rna
transcript
copi
per
reaction
ident
panhrsv
assay
tabl
linear
amplif
achiev
dynam
rang
copi
per
reaction
fig
specif
duplex
hrsv
rrtpcr
assay
evalu
high
concentr
total
nucleic
acid
extract
divers
collect
respiratori
pathogen
includ
adenoviru
human
metapneumoviru
rhinoviru
parainfluenza
virus
influenza
virus
coronavirus
human
bocaviru
mycoplasma
pneumonia
streptococcu
pneumonia
supplementari
tabl
fals
posit
result
obtain
sampl
addit
hrsv
primerprob
sequenc
evalu
silico
blastn
analysi
queri
combin
homolog
human
genom
respiratori
tract
pathogen
commens
observ
would
predict
potenti
fals
posit
result
assay
reproduc
assess
use
three
rna
transcript
concentr
copiesreact
repres
rang
hrsv
ct
valu
found
posit
clinic
specimen
see
intraassay
variat
estim
four
replic
three
transcript
concentr
test
singl
run
interassay
variat
estim
four
ident
replic
test
twice
two
separ
day
intraassay
coeffici
variat
cv
rang
interassay
cv
rang
tabl
assay
clinic
perform
assess
respiratori
specimen
previous
test
posit
hrsv
specimen
fig
amplif
plot
standard
curv
serial
dilut
rang
curv
curv
copiesreact
rna
transcript
analyz
duplex
hrsv
panhrsv
rrtpcr
assay
plot
insert
show
calcul
linear
correl
coeffici
assay
fig
confirm
retest
sequenc
reveal
singl
base
substitut
duplex
assay
revers
primer
would
predict
diminish
amplif
effici
review
recent
hrsv
genom
deposit
genbank
follow
studi
complet
found
sequenc
contain
two
singl
base
substitut
primerprob
region
duplex
assay
would
also
predict
compromis
perform
one
forward
primer
near
middl
rsv
b
probe
eg
review
sequenc
obtain
clinic
specimen
studi
found
two
ident
substitut
unpublish
result
interestingli
ct
valu
obtain
duplex
pan
assay
specimen
nearli
ident
suggest
two
substitut
deleteri
effect
duplex
assay
studi
develop
valid
duplex
rrtpcr
assay
detect
subgroupspecif
identif
hrsv
use
current
avail
sequenc
genbank
duplex
assay
prove
sensit
specif
correctli
identifi
hrsv
subgroup
divers
collect
hrsv
posit
clinic
specimen
compar
perform
previous
report
pan
hrsv
refer
assay
fri
et
al
achiev
longterm
efficaci
assay
face
continu
hrsv
genom
evolut
target
conserv
region
nucleoprotein
gene
nucleoprotein
gene
offer
ad
advantag
locat
nearer
enhanc
transcript
gradient
yield
increas
potenti
target
theoret
improv
test
sensit
cowton
et
al
primer
probe
design
also
includ
degeneraci
mix
base
allel
long
intern
quench
probe
exhibit
lower
background
fluoresc
toler
sequenc
polymorph
duplex
rrtpcr
assay
offer
sever
import
advantag
previou
assay
design
earlier
assay
handicap
limit
sequenc
data
avail
primerprob
design
sequenc
avail
often
archaic
highli
passag
cultur
isol
repres
natur
occur
hrsv
strain
kuyper
et
al
perkin
et
al
abl
take
advantag
greatli
expand
hrsv
genom
data
made
avail
j
craig
venter
institut
genom
center
infecti
diseas
http
gcid
other
moreov
assay
valid
newer
commerci
singlestep
rrtpcr
enzym
kit
offer
improv
amplif
effici
reduc
setup
time
previous
avail
chose
target
hrsv
nucleocapsid
gene
assay
develop
rel
conserv
compar
genom
region
assay
target
g
glycoprotein
gene
tan
et
al
show
highest
sequenc
variabl
subject
increas
risk
primerprob
mismatch
destabil
anoth
older
assay
perkin
et
al
melt
temperatur
rrtpcr
probe
lower
correspond
primer
would
result
lower
percentag
probe
bound
target
amplif
cycl
compromis
assay
sensit
rodriguez
et
al
exploit
short
region
homolog
hrsv
genom
primerprob
target
assay
use
short
probe
groov
binder
mgb
moieti
increas
stabil
probetarget
hybrid
kuyper
et
al
et
al
howev
mgb
probe
origin
design
detect
singl
nucleotid
polymorph
inher
suscept
base
mismatch
destabil
whiley
sloot
yao
et
al
commerci
molecular
assay
hrsv
packag
individu
part
larger
respiratori
pathogen
panel
certifi
vitro
diagnost
use
us
intern
agenc
seemingli
attract
altern
reddington
et
al
howev
commerci
assay
also
vulner
potenti
variant
dropout
costli
often
depend
dedic
equip
oligonucleotid
sequenc
use
typic
proprietari
inaccess
end
user
assess
compat
current
circul
hrsv
strain
moreov
primerprob
chang
need
accommod
new
genet
variant
regulatori
requir
delay
implement
final
hrsv
subgroup
assay
requir
primerprob
perform
perkin
et
al
assay
requir
four
oligonucleotid
subgroup
identif
seven
total
combin
pan
rrtpcr
assay
recent
studi
kamau
collabor
kamau
et
al
identifi
hrsv
subgroup
b
variant
fail
detect
establish
rrtpcr
assay
gunson
et
al
sequenc
identifi
mismatch
base
probe
central
region
disrupt
probetempl
anneal
author
design
replac
assay
correct
problem
provid
valid
data
document
assay
perform
variant
discov
hospit
children
routin
screen
hrsv
ifa
method
less
suscept
viru
strain
variat
howev
routin
ifa
screen
impract
would
less
effect
test
adult
method
would
lack
requisit
sensit
even
updat
sequenc
also
encount
singl
hrsv
strain
poorli
amplifi
duplex
assay
sequenc
reveal
singl
nucleotid
mismatch
revers
primer
although
gener
toler
probe
suss
et
al
whiley
sloot
primer
mismatch
also
diminish
target
amplif
blai
et
al
although
occasion
hrsv
variant
elud
molecular
detect
would
expect
greatli
impact
hrsv
diseas
burden
estim
hrsv
variant
quickli
replac
compet
strain
occur
novel
ba
viru
emerg
fig
comparison
duplex
hrsv
panhrsv
rrtpcr
assay
hrsv
hrsv
b
singl
posit
clinic
specimen
linear
regress
line
fit
cycl
threshold
ct
data
regress
equat
coeffici
determin
inset
outlier
sampl
select
retest
common
hrsv
b
lineag
detect
worldwid
trento
et
al
trento
et
al
simultan
test
specimen
duplex
pan
rrtpcr
assay
would
reduc
risk
undetect
hrsv
variant
dropout
blai
et
al
conclus
develop
duplex
rrtpcr
assay
rapid
sensit
specif
detect
simultan
subgroup
identif
hrsv
use
current
avail
genom
sequenc
data
genbank
assay
appli
outbreak
investig
surveil
studi
obtain
baselin
inform
regard
circul
hrsv
subgroup
serv
refer
standard
assay
achiev
compar
hrsv
diseas
burden
estim
find
conclus
report
author
necessarili
repres
offici
posit
center
diseas
control
prevent
particip
particip
guardian
provid
inform
consent
ethic
approv
surveil
activ
respiratori
diseas
specimen
retent
obtain
collabor
site
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
supplementari
materi
relat
articl
found
onlin
version
doi
http
